Dechra Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Dechra Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 1.1%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un descenso anual de 1.7%. Los ingresos han ido creciendo a una tasa media de 12.2% al año.

Información clave

1.1%

Tasa de crecimiento de los beneficios

-0.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Pharmaceuticals	7.3%
Tasa de crecimiento de los ingresos	12.2%
Rentabilidad financiera	-3.7%
Margen neto	-3.7%
Última actualización de beneficios	30 Jun 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Dechra Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:1PK Ingresos, gastos y beneficios (GBP Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 23	762	-28	352	61
31 Mar 23	744	6	316	55
31 Dec 22	727	40	280	49
30 Sep 22	704	49	267	43
30 Jun 22	682	58	253	36
31 Mar 22	661	66	239	35
31 Dec 21	641	73	225	35
30 Sep 21	624	64	224	36
30 Jun 21	608	56	222	37
31 Mar 21	587	50	215	36
31 Dec 20	566	44	208	35
30 Sep 20	541	39	203	35
30 Jun 20	515	34	199	34
31 Mar 20	507	31	200	34
31 Dec 19	499	29	201	33
30 Sep 19	490	30	198	32
30 Jun 19	482	31	196	32
31 Mar 19	463	28	191	31
31 Dec 18	444	25	186	29
30 Sep 18	426	30	171	28
30 Jun 18	407	36	156	26
31 Mar 18	394	40	147	26
31 Dec 17	381	43	137	26
30 Sep 17	370	35	133	26
30 Jun 17	359	26	129	26
31 Mar 17	334	19	122	23
31 Dec 16	309	11	115	19
30 Sep 16	278	12	105	15
30 Jun 16	248	13	95	10
31 Mar 16	230	17	90	10
31 Dec 15	213	20	84	9
30 Sep 15	208	20	82	9
30 Jun 15	203	19	81	9
31 Mar 15	201	21	79	8
31 Dec 14	199	22	77	8
30 Sep 14	196	21	75	8
30 Jun 14	194	19	74	8
31 Dec 13	193	14	73	8
30 Sep 13	191	13	73	8
30 Jun 13	189	11	72	8

Ingresos de calidad: 1PK actualmente no es rentable.

Margen de beneficios creciente: 1PK actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: 1PK no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 1.1% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de 1PK en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: 1PK no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (3.8%).

Rentabilidad financiera

Alta ROE: 1PK tiene una rentabilidad financiera negativa (-3.69%), ya que actualmente no es rentable.

Dechra Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Recent updates

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Investor sentiment improves as stock rises 33%

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Now 20% undervalued after recent price drop

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 22% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Now 21% undervalued after recent price drop

Less than half of directors are independent

Non-Executive Chairman recently bought €119k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Upcoming dividend of UK£0.29 per share

Board Member recently sold €1.0m worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold €1.1m worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: €41.36

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: €38.84

CEO, MD & Executive Director recently sold €12m worth of stock

Dechra Pharmaceuticals PLC Launches Mirataz

Upcoming Dividend of UK£0.24 Per Share

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

New 90-day high: €38.52

Non-Executive Director recently bought €28k worth of stock

Non-Executive Director recently bought €28k worth of stock

Independent Non Executive Director recently sold €142k worth of stock

Full year earnings released - EPS €0.33

New 90-day high - €36.48

New 90-day high - €33.70

New 90-day high - €32.96

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado

Desglose de ingresos y gastos
Beta